Why the study?
Little is known about how progressive primary hypokalemic periodic paralysis myopathy is, requiring natural history data and biomarkers for disease monitoring and trials.
Does quantitative muscle MRI detect disease progression in patients with hypokalemic periodic paralysis?
Does quantitative muscle MRI detect disease progression in patients with hypokalemic periodic paralysis?
Quantitative muscle MRI can detect subclinical disease progression in hypokalemic periodic paralysis over a median 20-month follow-up, whereas muscle strength testing does not.
Answers are grounded in this paper and cite their sources.
Supports quantitative muscle MRI for detecting subclinical progression in hypokalemic periodic paralysis; hypothesis-generating and requires prospective validation before clinical adoption.
Background and Objectives: Primary hypokalemic periodic paralysis (HypoPP) is a muscle channelopathy that can cause periodic paralysis and permanent weakness. Currently, little is known about how progressive this myopathy is. Natural history data for HypoPP can potentially answer the question of progressiveness and form the basis for outcome measures to be used in follow-up and emerging treatment trials. We aimed to describe the natural history of HypoPP and assess whether quantitative fat imaging is a valuable biomarker to monitor disease progression. Methods: In this prospective follow-up study, we examined disease progression using Dixon MRI to monitor changes in fat replacement of the muscle and stationary dynamometry to monitor changes in muscle strength. Three participants were asymptomatic carriers, 22 had periodic paralysis, 3 had permanent weakness, and 9 had periodic paralysis in combination with permanent weakness. The median follow-up time was 20 months (range 12-25). We found that fat fraction increased in 10 of 21 examined muscles. An increase in the composite fat fraction of at least 1 muscle group was found in all symptomatic phenotypes. By contrast, we found no significant change in muscle strength. Discussion: The results from this follow-up study support the use of quantitative muscle MRI to monitor subclinical disease progression in HypoPP in patients with and without attacks of paralysis.
No takes yet. Share an insight, caveat, or question.
Holm‐Yildiz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: